Find Clinical Trials

Back I am newly diagnosed Not yet treated

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

I want to enter information about my cancer and treatments

I want to enter information about my genetic testing (e.g, BRCA) and/or tumor testing results

I want to filter the trials based on location, phase of development, tumor genomic alteration, or drug name, category or target

Matching Trials

For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.

III

Newly diagnosed BRCA WT and HRD- stage III/IV ovarian cancer following optimal cytoreduction at primary or interval surgery

A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma

AZ, CA, CO, CT, FL, GA, HI, IN, LA, MA, MI, MN, NE, NJ, NY, NC, OH, OK, PA, RI, SD, TN, TX, VA, WA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Oregovomab	OvaRex, Monoclonal Antibody B43.13, B43.13	Immune response against cancer expressing CA125	Clinical Trials
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

III

Newly diagnosed stage III ovarian cancer eligible for primary cytoreductive surgery

Phase III Randomized Clinical Trial for Stage III Epithelial Ovarian Cancer Randomizing Between Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy

NY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Cisplatin	CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin	DNA damaging agent	Approved in Ovarian Cancer
HIPEC	Hyperthermic Intraperitoneal Chemotherapy		NCCN Guidelines for Ovarian Cancer

III

Newly diagnosed stage II-IV low grade serous ovarian cancer that is TP53 WT

A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

AK, AZ, AR, CA, CO, CT, DE, DC, FL, GA, HI, ID, IL, IN, IA, KS, KY, LA, ME, MD, MA, MI, MN, MS, MO, MT, NE, NV, NJ, NM, NY, NC, ND, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, WA, WV, WI, WY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Letrozole	Femara	Aromatase inhibitor	NCCN Guidelines for Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

II

Newly diagnosed stage III/IV low grade serous ovarian cancer (neo-adjuvant)

A Pilot Phase II Study of Neoadjuvant Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Abemaciclib	Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio	CDK4/6 inhibitor	Approved in Other Cancers
Fulvestrant	Faslodex, ICI 182,780, ZD9238	ER antagonist (SERD)	Approved in Other Cancers

II

Newly diagnosed stage III-IV high grade serous FRalpha+ ovarian cancer (neoadjuvant)

Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer Who Are Folate Receptor α Positive

AL

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Mirvetuximab soravtansine	M9346A-sulfo-SPDB-DM4, IMGN853, Anti-FOLR1-mab Maytansinoid Conjugate	ADC: anti-FOLR1 + microtubule destabilizer (DM4)	Clinical Trials

II

Newly diagnosed stage III/IV high grade ovarian cancer (neo-adjuvant)

Phase II Single Arm Study of Combination Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Ovarian, Fallopian Tube, or Peritoneal Carcinoma Receiving Neoadjuvant Chemotherapy

FL

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer
Pembrolizumab	Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

Ib

Newly diagnosed suspected stage III/IV ovarian cancer (neo-adjuvant)

Phase 1B Trial With PTC-596 in High-Grade Serous Ovarian Cancer: a Targeted Approach Toward Chemoresistant Stem-Like Cancer Cells

OK

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer
PTC596	BMI1 inhibitor PTC596, polycomb ring finger oncogene inhibitor PTC596	BMI1 inhibitor	Clinical Trials

I/II

Newly diagnosed stage III/IV ovarian cancer (neo-adjuvant) (Phase II)

A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

AL, CA, FL, MA, MO, NJ, NY, OK, OR, SD, TN, WA, WI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
GEN-1	PEG-PEI-cholesterol lipopolymer-encased IL-12 DNA plasmid vector GEN-1, EGEN-001, phIL-12-005/PPC	IL-12 receptor agonist	Clinical Trials
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

I

Newly diagnosed stage II-IV, BRCA MUT, mixed epithelial carcinoma, high grade serous or endometrioid ovarian cancer (neo-adjuvant)

BrUOG 390: Neoadjuvant Treatment With Talazoparib for Women With Newly Diagnosed, Advanced Ovarian Cancer Associated With a Mutation in BRCA1 or BRCA2 (mBRCA)

RI

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Talazoparib	MDV3800, BMN-673, Talazoparib Tosylate, Talzenna	PARP inhibitor	Approved in Other Cancers

I

Ovarian cancer with no evidence of disease after first-line treatment

Phase 1b Study of INO-5401 Alone or INO-5401 in Combination With INO-9012 Followed by Electroporation in Adult Cancer and Non-Cancer Patients With BRCA1 or BRCA2 Mutations

PA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
INO-5401	WT1/PSMA/hTERT-encoding plasmid DNA INO-5401	Immune response against cancer expressing hTERT, PMSA or WT1	Clinical Trials
INO-9012	DNA plasmid encoding interleukin-12 INO-9012	IL-12 receptor agonist	Clinical Trials

I

Newly diagnosed high grade serous ovarian cancer

A Pilot Study of Wee1 Inhibition Induction Prior to Tumor Reductive Surgery in Ovarian Cancer

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Adavosertib	WEE1 inhibitor AZD1775, MK1775, AZD1775	WEE1 inhibitor	Clinical Trials

I

Newly diagnosed stage III/IV ovarian cancer (neo-adjuvant) or platinum sensitive recurrent ovarian cancer (at first recurrence) (neo-adjuvant or adjuvant and maintenance)

NeoVax With Nivolumab in Patients With Ovarian Cancer

MA

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
NeoVax		Immune response against neoantigens	Clinical Trials
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers

I

Ovarian cancer with peritoneal disease - expected to undergo complete cytoreduction

Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies

MD

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Cisplatin	CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin	DNA damaging agent	Approved in Ovarian Cancer
Doxorubicin	14-Hydroxydaunomycin, Hydroxyl-Daunorubicin	Topoisomerase II inhibitor	Approved in Other Cancers
Floxuridine	WR-138720, 5-FUDR	RNA and DNA synthesis inhibitor
HIPEC	Hyperthermic Intraperitoneal Chemotherapy		NCCN Guidelines for Ovarian Cancer
Mitomycin C	Ametycine, MITO-C, Mitocin, Mitolem, Mitosol, Mitozytrex, Mutamycin, NCI-C04706	DNA synthesis inhibitor	Approved in Other Cancers
Oxaliplatin	OHP, Eloxatine, Dacplat, Dacotin, Eloxatin	DNA damaging agent
Surgery			Clinical Trials

I

Newly diagnosed BRCA MUT ovarian cancer (neo-adjuvant)

NOW: Neoadjuvant Olaparib Window Trial in Newly Diagnosed BRCA-Mutant Ovarian Cancer

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Olaparib	AZD2281, Lynparza	PARP inhibitor	Approved in Ovarian Cancer

I

Newly diagnosed ovarian cancer or TNBC (neo-adjuvant)

Pre-Surgical Window Pilot Investigation of the Effect of PARP Inhibition on the Cellular and Molecular Changes in Primary Ovarian and Breast Cancer

TX

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Olaparib	AZD2281, Lynparza	PARP inhibitor	Approved in Ovarian Cancer

I

Newly diagnosed stage III/IV high grade serous ovarian cancer (neo-adjuvant)

A Pilot Study of Nivolumab With or Without Ipilimumab in Combination With Front-Line Neoadjuvant Dose Dense Paclitaxel and Carboplatin Chemotherapy and Post-Surgical Dose Dense Paclitaxel and Carboplatin Chemotherapy in Patients With High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NY

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent	Approved in Ovarian Cancer
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells	Approved in Other Cancers
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells	Approved in Other Cancers
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor	Approved in Ovarian Cancer

I

High grade serous ovarian cancer with complete response after surgery and first-line platinum therapy (w/ banked tumor tissue)

A Phase I Trial Evaluating a Mutanome-directed Immunotherapy in Patients With High Grade Serous Carcinoma (HGSC) of the Ovary, Fallopian Tube or Peritoneum.

AZ, FL, MN

Drug(s) in Trial	Other Drug Names	Main Known Action	Drug Status
TG4050	Modified Vaccinia Ankara (MVA) personalized vaccine, MyVAC	Immune response against neoantigens	Clinical Trials

If you have any questions or would like help with your search, please call us at: 858-657-0282 or email us at patientsupport@clearityfoundation.org.